Literature DB >> 10979914

Diversity and prevalence of PorA types in Neisseria meningitidis serogroup B in the United States, 1992-1998.

C T Sacchi1, A M Whitney, T Popovic, D S Beall, M W Reeves, B D Plikaytis, N E Rosenstein, B A Perkins, M L Tondella, L W Mayer.   

Abstract

Two hundred eighty-one sporadic Neisseria meningitidis serogroup B isolates, collected through active laboratory-based surveillance, were selected to be analyzed by PorA variable region (VR) typing to determine the prevalence of PorA types in the United States. A substantial number of distinct VR types were identified, 31 in VR1 and 41 in VR2. A total of 73 different PorA types were found, and 76. 7% of these types comprise nonprototype sequences in VR1, VR2, or both. The most prevalent PorA types were P1.7,16-20 (previously P1.7, 16i), P1.22,14, P1.22-1,14 (previously P1.22a,14), P1.7,16, P1.7-1,1 (previously P1.7d,1), P1.19,15, and P1.17,16-3 (previously P1.B,16d). No correlation was observed between the PorA types and geographic origin of the isolates. These data may aid in the design of an efficacious outer membrane protein-based vaccine by identifying the most appropriate PorA types for vaccine formulation. Studies are needed to fully evaluate the extent of cross-protection in humans among the variants and prototypes in each PorA VR family.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10979914     DOI: 10.1086/315833

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  25 in total

1.  Molecular epidemiology of Neisseria meningitidis isolates from an outbreak of meningococcal disease among men who have sex with men, Chicago, Illinois, 2003.

Authors:  Susanna Schmink; John T Watson; Garry B Coulson; Roderick C Jones; Pamela S Diaz; Leonard W Mayer; Patricia P Wilkins; Nancy Messonnier; Susan I Gerber; Marc Fischer
Journal:  J Clin Microbiol       Date:  2007-08-29       Impact factor: 5.948

Review 2.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

3.  A critical threshold of meningococcal factor H binding protein expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicle vaccines.

Authors:  Oliver Koeberling; Isabel Delany; Dan M Granoff
Journal:  Clin Vaccine Immunol       Date:  2011-03-02

4.  Invasive meningococcal disease in Quebec, Canada, due to an emerging clone of ST-269 serogroup B meningococci with serotype antigen 17 and serosubtype antigen P1.19 (B:17:P1.19).

Authors:  Dennis K S Law; Manon Lorange; Louise Ringuette; Réjean Dion; Michel Giguère; Averil M Henderson; Jan Stoltz; Wendell D Zollinger; Philippe De Wals; Raymond S W Tsang
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

Review 5.  Molecular techniques for the investigation of meningococcal disease epidemiology.

Authors:  M C Maiden; M Frosch
Journal:  Mol Biotechnol       Date:  2001-06       Impact factor: 2.695

6.  First Use of a Serogroup B Meningococcal Vaccine in the US in Response to a University Outbreak.

Authors:  Lucy A McNamara; Alice M Shumate; Peter Johnsen; Jessica R MacNeil; Manisha Patel; Tina Bhavsar; Amanda C Cohn; Jill Dinitz-Sklar; Jonathan Duffy; Janet Finnie; Denise Garon; Robert Hary; Fang Hu; Hajime Kamiya; Hye-Joo Kim; John Kolligian; Janet Neglia; Judith Oakley; Jacqueline Wagner; Kathy Wagner; Xin Wang; Yon Yu; Barbara Montana; Christina Tan; Robin Izzo; Thomas A Clark
Journal:  Pediatrics       Date:  2015-05       Impact factor: 7.124

Review 7.  The discovery and development of a novel vaccine to protect against Neisseria meningitidis Serogroup B Disease.

Authors:  Gary W Zlotnick; Thomas R Jones; Paul Liberator; Li Hao; Shannon Harris; Lisa K McNeil; Duzhang Zhu; John Perez; Joseph Eiden; Kathrin U Jansen; Annaliesa S Anderson
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

8.  Phenotypic and genetic characterization of a unique variant of serogroup C ET-15 meningococci (with the antigenic formula C:2a:P1.7,1) causing invasive meningococcal disease in Quebec, Canada.

Authors:  Raymond S W Tsang; Chao Ming Tsai; Peixuan Zhu; Louise Ringuette; Manon Lorange; Dennis K S Law
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

Review 9.  Meningococcal carriage and disease--population biology and evolution.

Authors:  Dominique A Caugant; Martin C J Maiden
Journal:  Vaccine       Date:  2009-05-21       Impact factor: 3.641

10.  Molecular epidemiology of meningococcal disease in England and Wales 1975-1995, before the introduction of serogroup C conjugate vaccines.

Authors:  Joanne E Russell; Rachel Urwin; Stephen J Gray; Andrew J Fox; Ian M Feavers; Martin C J Maiden
Journal:  Microbiology (Reading)       Date:  2008-04       Impact factor: 2.777

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.